A New Generation of Treatments for Itch

Acta Derm Venereol. 2020 Jan 7;100(2):adv00027. doi: 10.2340/00015555-3347.

Abstract

For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.

Keywords: antipruritics; cytokines; pruritus; unmyelinated nerve fibers.

Publication types

  • Review

MeSH terms

  • Animals
  • Antipruritics / adverse effects
  • Antipruritics / therapeutic use*
  • Chronic Disease
  • Humans
  • Molecular Targeted Therapy
  • Pruritus / diagnosis
  • Pruritus / drug therapy*
  • Pruritus / etiology
  • Pruritus / metabolism
  • Risk Factors
  • Signal Transduction
  • Treatment Outcome

Substances

  • Antipruritics